639 related articles for article (PubMed ID: 30581877)
1. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.
Morelli M; Scarponi C; Mercurio L; Facchiano F; Pallotta S; Madonna S; Girolomoni G; Albanesi C
J Immunol Res; 2018; 2018():7897263. PubMed ID: 30581877
[TBL] [Abstract][Full Text] [Related]
2. Kaempferol modulates IFN-γ induced JAK-STAT signaling pathway and ameliorates imiquimod-induced psoriasis-like skin lesions.
Li Y; Cui H; Li S; Li X; Guo H; Nandakumar KS; Li Z
Int Immunopharmacol; 2023 Jan; 114():109585. PubMed ID: 36527884
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
Srivastava A; Ståhle M; Pivarcsi A; Sonkoly E
Acta Derm Venereol; 2018 Aug; 98(8):772-775. PubMed ID: 29738047
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib for the treatment of moderate-to-severe psoriasis.
Chiricozzi A; Faleri S; Saraceno R; Bianchi L; Buonomo O; Chimenti S; Chimenti MS
Expert Rev Clin Immunol; 2015 Apr; 11(4):443-55. PubMed ID: 25666451
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Krueger J; Clark JD; Suárez-Fariñas M; Fuentes-Duculan J; Cueto I; Wang CQ; Tan H; Wolk R; Rottinghaus ST; Whitley MZ; Valdez H; von Schack D; O'Neil SP; Reddy PS; Tatulych S;
J Allergy Clin Immunol; 2016 Apr; 137(4):1079-1090. PubMed ID: 27059729
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.
Calama E; Ramis I; Domènech A; Carreño C; De Alba J; Prats N; Miralpeix M
Pulm Pharmacol Ther; 2017 Apr; 43():60-67. PubMed ID: 28087469
[TBL] [Abstract][Full Text] [Related]
7. Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.
Hashimoto T; Sakai K; Sanders KM; Yosipovitch G; Akiyama T
Acta Derm Venereol; 2019 Mar; 99(3):298-303. PubMed ID: 30460374
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
[TBL] [Abstract][Full Text] [Related]
9. Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes.
Sun S; Zhang X; Xu M; Zhang F; Tian F; Cui J; Xia Y; Liang C; Zhou S; Wei H; Zhao H; Wu G; Xu B; Liu X; Yang G; Wang Q; Zhang L; Gong Y; Shao C; Zou Y
Cell Death Dis; 2019 Mar; 10(4):274. PubMed ID: 30894513
[TBL] [Abstract][Full Text] [Related]
10. Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing γδ T cells.
Xie XJ; Di TT; Wang Y; Wang MX; Meng YJ; Lin Y; Xu XL; Li P; Zhao JX
Mol Immunol; 2018 Sep; 101():386-395. PubMed ID: 30064075
[TBL] [Abstract][Full Text] [Related]
11. JAK1/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis.
Clarysse K; Pfaff CM; Marquardt Y; Huth L; Kortekaas Krohn I; Kluwig D; Lüscher B; Gutermuth J; Baron J
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):367-375. PubMed ID: 30357932
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.
Gao W; McGarry T; Orr C; McCormick J; Veale DJ; Fearon U
Ann Rheum Dis; 2016 Jan; 75(1):311-5. PubMed ID: 26353790
[TBL] [Abstract][Full Text] [Related]
14. Astilbin inhibits Th17 cell differentiation and ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via Jak3/Stat3 signaling pathway.
Di TT; Ruan ZT; Zhao JX; Wang Y; Liu X; Wang Y; Li P
Int Immunopharmacol; 2016 Mar; 32():32-38. PubMed ID: 26784569
[TBL] [Abstract][Full Text] [Related]
15. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
16. Suppression of IL-12/IL-23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon-γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon-driven diseases.
Vincken NLA; Welsing PMJ; Silva-Cardoso SC; Bekker CPJ; Lopes AP; Olde Nordkamp M; Leijten EFA; Radstake TRDJ; Angiolilli C
Exp Dermatol; 2022 Jun; 31(6):962-969. PubMed ID: 35297512
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Berekmeri A; Mahmood F; Wittmann M; Helliwell P
Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
19. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
20. 3, 3'- diindolylmethane hinders IL-17A/IL-17RA interaction and mitigates imiquimod-induced psoriasiform in mice.
Srikanth M; Rasool M
Int Immunopharmacol; 2022 Aug; 109():108795. PubMed ID: 35487087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
